Results 41 to 50 of about 289,170 (184)

Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients

Diagnostic Pathology, 2013
Background Amplification of MYCN oncogene is an established marker indicating aggressive tumor progression of neuroblastoma (NBL). But copy number analyses of MYCN gene in ganglioneuroblastoma (GNBL) and ganglioneuroma(GN) is poorly described in the ...
Wang Miao, Zhou Chunju, Cai Rongqin, Li Yong, Gong Liping   +4 more
doaj   +1 more source

Neuroblastoma and MYCN [PDF]

, 2013
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor
Weiss, William A, Huang, Miller
core   +1 more source

MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma

Cell Death and Disease, 2021
MYCN amplification is tightly associated with the poor prognosis of pediatric neuroblastoma (NB). The regulation of NB cell death by MYCN represents an important aspect, as it directly contributes to tumor progression and therapeutic resistance. However,
Yuxiong Lu, Qing Yang, Yubin Su, Yin Ji, Guobang Li, Xianzhi Yang, Liyan Xu, Zhaoliang Lu, Jiajun Dong, Yi Wu, Jin-Xin Bei, Chaoyun Pan, Xiaoqiong Gu, Bo Li   +13 more
doaj   +1 more source

Analysis of candidate gene co-amplification with MYCN in neuroblastoma

Previous studies have revealed that the MYCN gene spans approximately 7 kb, while the amplicon has been estimated to be 100 kb to 1 Mb long [1-3]. This implies that several other genes may be present on the MYCN amplicon.
George RE, Lunec J, Kogner P, Kenyon R, Pearson ADJ, McGuckin AG, Christiansen H, Kohl N   +7 more
core   +4 more sources

Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study

Neoplasia: An International Journal for Oncology Research, 2001
To assess the utility of fluorescence in situ hybridization (FISH) for analysis of MYCN gene amplification in neuroblastoma, we compared this assay with Southern blot analysis using tumor specimens collected from 232 patients with presenting ...
Prasad Mathew, Marcus B. Valentine, Laura C. Bowman, Susan T. Rowe, Michael B. Nash, Virginia A. Valentine, Susan L. Cohn, Robert P. Castleberry, Garrett M. Brodeur, A. Thomas Look   +9 more
doaj   +1 more source

Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma

Cell Reports, 2020
Summary: Loss of heterozygosity (LOH) at 1p36 occurs in multiple cancers, including neuroblastoma (NBL). MYCN amplification and 1p36 deletions tightly correlate with markers of tumor aggressiveness in NBL.
Jesus García-López, Kirby Wallace, Joel H. Otero, Rachelle Olsen, Yong-dong Wang, David Finkelstein, Brian L. Gudenas, Jerold E. Rehg, Paul Northcott, Andrew M. Davidoff, Kevin W. Freeman   +10 more
doaj   +1 more source

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. [PDF]

Br J Cancer, 2018
In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA).
Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.   +23 more
europepmc   +7 more sources

Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells

Scientific Reports, 2022
Neuroblastoma is a childhood tumour that is responsible for approximately 15% of all childhood cancer deaths. Neuroblastoma tumours with amplification of the oncogene MYCN are aggressive, however, another aggressive subgroup without MYCN amplification ...
Sanja Jurcevic, Simon Keane, Emmy Borgmästars, Zelmina Lubovac-Pilav, Katarina Ejeskär   +4 more
doaj   +1 more source

Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults

Case Reports in Oncological Medicine, 2013
MYCN is a well-known oncogene overexpressed in different human malignancies including neuroblastoma, rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms’ tumor, and small cell lung cancer.
Anna Koumarianou, Panagiota Oikonomopoulou, Margarita Baka, Dimitrios Vlachodimitropoulos, Stylianos Argentos, Theodoros Piperos, Maria-Ioanna Christodoulou, Kakoulis Theodoulou, Theodoros Mariolis-Sapsakos   +8 more
doaj   +1 more source

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

Neoplasia: An International Journal for Oncology Research, 2013
Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate cancer, is a lethal tumor that most commonly arises in late stages of prostate adenocarcinoma (PCA) with predilection to metastasize to visceral organs.
Juan Miguel Mosquera, Himisha Beltran, Kyung Park, Theresa Y. MacDonald, Brian D. Robinson, Scott T. Tagawa, Sven Perner, Tarek A. Bismar, Andreas Erbersdobler, Rajiv Dhir, Joel B. Nelson, David M. Nanus, Mark A. Rubin   +12 more
doaj   +1 more source